Effect of erythropoietin combined with PCI on myocardial damage and vascular endothelial function in patients with STEMI

• Main Authors: Wei Huang, Ji-Tian Zhu, Qian Li
• Format: Article
• Language: English
• Published: Editorial Board of Journal of Hainan Medical University 2019-02-01
• Series: Journal of Hainan Medical University
• Online Access: http://www.hnykdxxb.com/PDF/201904/06.pdf
• ISSN: 1007-1237; 1007-1237

Objective: To investigate the effects of erythropoietin combined with percutaneous coronary intervention (PCI) on myocardial damage, vascular endothelial function and neuroendocrine hormone levels in patients with ST-segment elevation myocardial infarction (STEMI). Method: From August 2015 to February 2018, 80 patients with STEMI were selected from our hospital, divided into 2 groups according to admission time, 40 cases in each group, set to observation group and control group, the observation group was treated with erythropoietin combined with PCI, and the control group was treated only with PCI, to compare the degree of myocardial damage, vascular endothelial function and neuroendocrine hormone levels after treatment. Results: At 24 h after surgery, the observed group of cardiac troponin (cTNI), creatine kinase isoenzyme (CK-MB), type I collagen carboxy terminal peptide (ICTP) and ischemic modified albumin (IMA) is lower than the control group,the cystatin-C (Cys-C) level is higher than the control group, the difference was statistically significant (P<0.05); At 1 week after surgery, the levels of endothelin-1 (ET-1) and von Willebrand factor (vWF) in the observation group were lower than the control group, and the level of nitric oxide (NO) was higher than that in the control group, the difference was statistically significant (P<0.05); At 1 week after surgery, the levels of cortisol (Cor), adrenocortical hormone (ACTH), norepinephrine (NE) and Angiotensin II (AngII) in the observation group were lower than in the control group, the difference was statistically significant (P<0.05). Conclusion: Erythropoietin combined with PCI in the treatment of STEMI patients with better clinical effect, can effectively reduce the degree of myocardial damage, protect vascular endothelial cell function, improve the body's neuroendocrine hormone levels, recommend clinical application.